

IN THE CLAIMS

10/507498
DT04 Rec'd PCT/PTO 13 SEP 2004

Claim 1(original): A method of qualitative or quantitative assay of collagen type II or fragments thereof in a biological sample comprising contacting said fragments with an immunological binding partner which is immunoreactive with an epitope comprised in the amino acid sequence HRGYPGLDG and detecting resulting immunoreaction.

Claim 2(original): A method as claimed in claim 1, wherein said epitope consists of five or more amino acids in said sequence.

Claim 3(currently amended): A method as claimed in claim 1 ~~or claim 2~~, wherein said immunological binding partner is reactive with said epitope in the context of unwound collagen type II or fragments thereof but not in the context of the wound form of collagen type II.

Claim 4(currently amended): A method as claimed in claim 1 ~~any preceding claim~~, wherein the detected immunoreaction is between said immunological binding partner and collagen type II fragments of less than 80kDa.

Claim 5(original): A method as claimed in claim 4, wherein said fragments are of less than 30kDa.

Claim 6(original): A method as claimed in claim 4, wherein said fragments are of less than 10kDa.

Claim 7(currently amended): A method as claimed in claim 1 ~~any preceding claim~~, wherein said sample is a biological fluid.

Claim 8(original): A method as claimed in claim 7, wherein said biological fluid is serum, urine, tear fluid, synovial fluid, subcutaneous interstitial fluid, a cell culture supernatant fluid, or a cell extract.

Claim 9(currently amended): A method as claimed in claim 1 ~~any preceding claim~~, wherein said detected immunoreaction is indicative of degradation of cartilage.

Claim 10(original): An immunological binding partner which recognises an epitope derived from collagen type II which is comprised in the amino acid sequence HRGYPGLDG.

Claim 11(original): A binding partner as claimed in claim 10, which is reactive with said epitope in the context of unwound collagen type II or fragments thereof but not in the context of the wound form of collagen type II.

Claim 12(currently amended): A cell line producing a monoclonal assay which is an immunological binding partner as claimed in claim 10 ~~or claim 11~~.

Claim 13(original): A kit for performing an assay as claimed in claim 1 and comprising:

an immunological binding partner which is immunoreactive with an epitope comprised in the amino acid sequence HRGYPGLDG; and

means for detecting immunoreaction between said immunological binding partner and a sample.

Claim 14(original): A kit as claimed in claim 13, wherein said immunological binding partner bears a detectable label or is immobilised to a solid material.

Claim 15(currently amended): A kit as claimed in claim 13 ~~or claim~~
14, wherein said kit comprises a peptide which comprises said
epitope and competes with collagen type II or fragments thereof for
binding to said immunological binding partner.

Claim 16(original): A kit as claimed in claim 15, wherein said
peptide bears a detectable label or is immobilised to a solid
surface.